Abstract:Objective: To compare the chemosensitivity of pirarubicin (THP) and epirubicin (EPI) in primary breast cancer (PBC) cells so as to examine their differential chemosensitivity to THP and EPI by CD-DST (collagen gel droplet embedded culture-drug sensitivity test) system; To detect the differences in the short-term clinical efficacy and side effects between TAC (docetaxel + pirarubicin + cyclophosphamide) and TEC (docetaxel + epirubicin + cyclophosphamide) as the neoadjuvant chemotherapy regimens and the long-term clinical efficacy of CAF (cyclophosphamide + pirarubicin + fluorouracil) and CEF (cyclophosphamide + epirubicin + fluorouracil) as the chemotherapy regimens in breast cancer; To evaluate the feasibility of THP as an adjuvant chemotherapeutic regimen in the treatment of breast cancer. Methods: From January 2008 to January 2009, a total of 129 fresh breast cancer samples were collected. The differential chemosensitivity of cultured PBC cells to THP and EPI was measured by CD-DST test. And 139 cases of PBC patients inIIb-IIIc phase were randomly divided into two groups: TAC and TEC groups. After 4-6 cycles of neoadjuvant chemotherapy, the primary lesion, axillary lymph nodes and side effects were assessed; The clinical data and survival status of 1241 cases of PBC patients treated at our hospital from 2003 to 2006 were collected and divided into CAF and CEF groups according to their chemotherapeutic regimens. Long-term prognosis was compared between two groups. Results: There was no significant difference of chemosensitivity between THP and EPI in PBC cells (P = 0.743); The overall response rate (RR) of neoadjuvant chemotherapy was 87.8%; the clinical objective responses, pathologic complete remission (pCR), clinical complete remission (cCR), clinical partial remission (cPR) and stable disease (SD) of groups TAC and TEC were 88.7%, 11.3%, 28.2%, 60.6%, 11.3% vs 86.8%, 10.3%, 26.5%, 60.3%, 13.2% respectively. There was no significant difference between two groups (P > 0.05). No significant differences existed between two groups in such side effects as leukopenia, thrombocytopenia, constipation, cardiotoxity and hepatorenal dysfunction (P > 0.05). The gastrointestinal reactions of nausea and vomiting was less frequent in the TAC group than that in the TEC group (46.5% vs 66.2%, P = 0.019); There was no significant difference in 5-year disease-free survival rate (79% vs 78%) and overall survival rate between two groups (85% vs 82%, P > 0.05). Conclusion: There were no significant differences in chemosensitivity, clinical efficacy of neoadjuvant chemotherapy, side effects or long-term efficacy between THP and EPI. Both pirarubicin and epirubicin may be used as conventional chemotherapy in breast cancer.

The Electrocardiographic Comparison of Elderly Patient with Cancer after Chemotherapy Between ADM and THP

Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy.

A Clinical Comparison of Tetrahydropyranyl Adriamycin Vs. Adriamycin in the Treatment of Non-Hodgkin's Lymphoma

Clinical efficacy observation of Amiodarone and Metoprolol on elderly paients with coronary heart disease by cardiac arrhythmias

Comparable Efficacy and Less Toxicity of Pegylated Liposomal Doxorubicin Versus Epirubicin for Neoadjuvant Chemotherapy of Breast Cancer: a Case-Control Study

[Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow]

Comparison of Homoharringtonine and Daunorubicin Cardiotoxicity in Adults with Acute Promyelocytic Leukemia

Metabonomic Study on the Cumulative Cardiotoxicity of a Pirarubicin Liposome Powder

572P Cardiotoxicity in Chinese Cancer Patients Treated with 5-Fluorouracil or Capecitabine: A Multicenter Prospective Observational Study

[Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer]

A Comparison of the Clinical Study of Dilated Cardiomyopathy in the Elderly and the Younger

Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study

Efficacy And Cardiotoxicity Of Liposomal Doxorubicin-Based Chemotherapy In Advanced Breast Cancer: A Meta-Analysis Of Ten Randomized Controlled Trials

Clinical Analysis of the Effect of Contrast-enhanced Ultrasonography on Trans-arterial Chemoembolization for Advanced Liver Cancer in the Elderly

Elucidating the interplay of PPAR gamma inhibition and energy demand in adriamycin‐induced cardiomyopathy: In Vitro and In Vivo perspective

Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study

Clinical and prognostic features of acute promyelocytic leukemia in the elderly

A Comparison of High Dose Epirubicin in Single Administration and Multiple Administrations in CHOP Regimen for 72 Cases with Non-Hodgkin's Lymphoma(NHL)

A Retrospective Study to Compare the Use of Tacrolimus and Cyclosporine in Combination with Adriamycin in Post-Transplant Liver Cancer Patients

Comparison of the effcacy and safety of the combined treatment of transcatheter arterial chemoembolization and radiofrequency ablation with transcatheter arterial chemoembolization or radiofrequency ablation treatment alone in patients with primary hepatic carcinoma in China